

INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領 航 醫 藥 及 生 物 科 技 有 限 公 司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability) (於開曼群島註冊成立並於百慕達存續之有限公司)

(Stock Code股份代號: 399)

NOTIFICATION LETTER 通知信函

9 May 2024

Dear Registered Shareholders.

Innovative Pharmaceutical Biotech Limited (the "Company")

· Notice of publication of Connected Transactions — (i) Issue Of New Convertible Bonds Under Specific Mandate; (ii) Amendment To The Terms And Conditions Of The Existing Convertible Bonds; And (iii) Notice Of Special General Meeting and Form Of Proxy (the "Current Corporate Communication")

The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at http://www.ipb.asia/ and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications (Note). If you have elected to receive the Corporate Communications in printed form, the Current Corporate Communication is enclosed.

If you for any reason have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company's Branch share registrar in Hong Kong, Tricor Tengis Limited ("Branch Share Registrar") at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided mailing label (no stamp is needed if posted in Hong Kong) or by email to 399-ecom@hk.tricorglobal.com. The Company will promptly upon your request send the Current Corporate Communications to you in printed form free of charge.

It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the Branch Share Registrar at the above-mentioned address by post or by email to 399-ecom@hk.tricorglobal.com. If the Company does not have your functional email address, until such time that the functional email address is provided to the Branch Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications ("Notice of Publication") and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form.

Should you have any queries relating to this notification, please call the Branch Share Registrar's telephone hotline at (852) 2980 1333 from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays).

> Yours faithfully. **Innovative Pharmaceutical Biotech Limited**

Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; (g) a proxy form; and (h) Actionable

Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

各位登記股東:

領航醫藥及生物科技有限公司(「本公司」) — 刊發關連交易 — (i) 根據特別授權發行新可換股債券;(ii) 修訂現有可換股債券之條款及條件;及 (iii) 股東特別大會通告及代表委任表格(「本

本公司的本次公司通訊之中、英文版本已分別上載於本公司網站(<u>http://www.ipb.asia/</u>)及香港聯合交易所有限公司(「**聯交所**」)之網站(<u>www.hkexnews.hk</u>)(「網站版本」)。我們建議 閣下閱覽本公司本次及日後公司通訊(附註)的網站版本。如 閣下已選擇收取公司通訊的印刷本 隨函附上本次公司通訊。

閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本及欲索取本次公司通訊及日後公司通訊的印刷本,請填妥及簽署隨附 之回條,並以已預付郵費的郵寄標籤寄回本公司之香港股份過戶登記分處(「股份過戶登記分處」)卓佳登捷時有限公司(地址為香港夏慤道16號遠 東金融中心17樓)(如在香港投寄毋須貼上郵票),或電郵至399-ecom@hk.tricorglobal.com。本公司會因應 閣下之要求立即寄上公司通訊的印刷本 費用全免。

登記股東有責任提供有效的電子郵件地址。如 閣下尚未提供 閣下之電子郵件地址予本公司,或需更新 閣下之電子郵件地址,本公司建議 閣 下填妥及簽署隨附之回條,並按上述地址以郵寄方式交回本公司股份過戶登記分處或以電郵方式發送至399-ecom@hk.tricorglobal.com。如果本公司沒有收到 閣下的有效電子郵件地址, 閣下將(i)無法透過電子郵件方式收取以電子方式發送的公司通訊網站版本的登載通知(「登載通知」)及可供採取行動的公司通訊。本公司只能以印刷本方式向 閣下發送登載通知及可供採取行動的公司通訊。本公司只能以印刷本方式向 閣下發送登載通知及可供採取行動的公司通訊之印刷本予 閣下,直至股份過戶登記分 處收到 閣下有效的電子郵件地址為止。

倘 閣下對本通知有任何查詢,請於星期一至星期五(公眾假期除外)上午9時至下午6時,致電股份過戶登記分處熱線(852)29801333。

領航醫藥及生物科技有限公司

謹啓

2024年5月9日

附註:公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於(a)董事會報告,公司年度賬目連同核數 師報告以及(如適用)財務摘要報告;(b)中期報告及(如適用)中期摘要報告;(c)季度報告(如有);(d)會議通告;(c)上市文件;(f)通函;(g)代表委任表格;及(h)可 供採取行動的公司通訊。

可供採取行動的公司通訊是指任何涉及要求股東指示其擬如何行使其有關股東權利的公司通訊。

REPLY FORM 回條			
Γο : ε/ο	Innovative Pharmaceutical Biotech Limited (the "Company") (Stock Code: 399) (Incorporated in the Cayman Islands and continued in Bermuda with limited liability, Tricor Tengis Limited 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong	經 (「本) <i>(於【</i> 經卓	醫藥及生物科技有限公司 公司」)(股份代號:399) 周曼群島註冊成立並於百慕達存續之有限公司) 佳登捷時有限公司 夏慤道16號 金融中心17樓
Pai 甲	rt A 部 I/We would like to receive the Current Corporate Communication and 本人/我們現欲以下列方式收取本次公司通訊及將來所有公司	l all future Co] 通訊之印刷	rporate Communications in printed form in the manner indicated below: 本:
Please	mark "✔" in ONLY ONE of the following boxes 請從下列選擇中,僅在其中 I/We would like to receive a printed copy in the English language only; or 本人/我們現欲收取一份英文印刷本;或 I/We would like to receive a printed copy in the Chinese language only; or 本人/我們現欲收取一份中文印刷本;或 I/We would like to receive a printed copy in both the English language and the 本人/我們現欲收取英文和中文各一份印刷本。		
	rt B I/We would like to receive all future Corporate Communications and 本人/我們現欲以以下電郵地址電子郵件方式收取本公司所有		rporate Communications in electronic form via the email address below: 通訊及可供採取行動的公司通訊的登載通知:
Please (請以:	provide the email address in English Capital Letters) 英文正楷填寫電郵地址)		
Name(: 投東姓	s) of Shareholder(s): 名:	Signature: 簽名:	
Addres 也址# _	(Please use BLOCK LETTERS請用正楷填寫)		(Please use BLOCK LETTERS請用正楷填寫
	t telephone number: 話號碼:	Date: 日期:	
Please complete and sign this form and return it by cutting and sticking the mailing label on an envelope to the Company's branch share registrar in Hong Kong, Tricor Tengis Limited or via email to 399-ecom@hk.tricorglobal.com。 常境 受及餐署 未支格,並以随附的郵奇標籤貼於信封上,帝同本公司之香港股份總戶登記分處单住登捷時有限公司,或電郵至399-ecom@hk.tricorglobal.com。 Please complete this form clearly, Any form with no indicated choice, with no signature or otherwise incorrectly completed shall be void. If your shares are held in joint names, the shareholder whose name stands first on the register of member of the Company in respect of the joint holding should sign on this form in order to be valid. 清清楚填写不影体。同僚上名未有作也理解,没有签名或没有正確地填写,均屬無效。如屬聯名股東,用本回條損疾本公司更来名册上哪名特有之股份戶口,由其处名列於首位的股東簽署,方為有效。 The above instruction for part A will apply to all future Corporate Communications to be sent to you until you notify otherwise by reasonable notice in writing to the Company's branch share registrar in Hong Kong or until expired on the lad day of the following financial year of the Company (whichever is earlier). Further request in writing will be required if a shareholder prefers to continue receiving printed copy of future Corporate Communications to be sent to you until you notify otherwise by reasonable notice in writing to the Company's branch share registrar in Hong Kong or until expired on the lad day of the following financial year of the Company (whichever is earlier). Further request in writing will be required if a shareholder prefers to continue receiving printed copy of future Corporate Communications to be sent to you until you notify otherwise by reasonable notice in writing to the Company branch share registrar in Hong Kong or the following financial year of the Company (whichever is earlier). Further requesting for a printed form of the Corporate Communications are combined in the register of the company for the midrost of the Corporate Communications of the Corporate Communications of the Corporate Communications of the Corporate Communications are combined into			
/our supp /ou have 本聲明中 閣下是自	PERSONAL INFORMATION COLLECTOR In this statement has the same meaning as "personal data" defined in the Personal Data (Privacy) Ordinance, Cap. bly of Personal Data is on a voluntary basis for the purpose of receiving Corporate Communications in the manner the right to request access to and/or to correct the respective Personal Data in accordance with the provisions of the PI 所指的[個人資料]具有香港法例第 486章(個人資料 (私聽條例))「電風騰條例》」「個人資料的海關向本公司提供關「個人資料」(因以 関下所獨之方式教收金樂組訊。 關下的個人資料的在場份,是我的基本提供《私聽條例》的條文要求查閱及/或修改 關下的個人資料。任何該等要求均須以書面方式提上	486 (the "PDPO"), chosen. Your Perso DPO. Any such req 函義,包括但不區 窗當期間保留作标	which may include but not limited to your name, contact telephone number, email address and mailing address nail Data will be retained for such period as may be necessary for our verification and record purposes. next for access to and/or correction of the Personal Data should be in writing by either of the following mean
	By mail to: Data Privacy Officer Tricor Tengis Limited 17/F, Far East Finance Centre 16 Harcourt Road, Hong Kong By email to: is-enquiries@hk.tricorglobal.com	經郵寄:經郵寄:經電郵:	個人資料私應主任 卓住營捷時有限公司 香港夏懿道16號 遠東金廳中心17樓 is-enquiries@hk.tricorglobal.com

Please cut the mailing label and stick it on an envelope

to return this Request Form to us. No postage is necessary if posted in Hong Kong. 閣下寄回本申請表格時,請將郵寄標籤剪貼於信封上。

如在本港投寄,閣下無需支付郵費或貼上郵票。

Mailing Label郵寄標籤

Tricor Tengis Limited 卓佳登捷時有限公司

Freepost No. 簡便回郵號碼:10 GPO Hong Kong 香港
Innovative Pharmaceutical Biotech Limited

領航醫藥及生物科技有限公司 (399)